EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, Myeloma22 September 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, Myeloma18 September 2023
European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, Myeloma22 August 2023
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, Myeloma14 August 2023
Watch the recording of the EHA 2023 highlights webinarAL amyloidosis, MPE, Myeloma, Videos10 July 2023
Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern EuropeAccess, Myeloma25 June 2023
